vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-624Research ArticleВ ПОМОЩЬ ВРАЧУA DOCTOR’S AIDИнгаляционные антибиотики — залог контроля над инфекцией у детей с муковисцидозомINHALATION ANTIBIOTICS ARE ESSENTIAL FOR THE CONTROL OF INFECTION IN CHILDREN WITH CYSTIC FIBROSISСимоноваО.И.SimonovaO.I.oisimonova@mail.ruЧистяковаВ.П.ChistyakovaV.P.neonatepearl@yandex.ruЛазареваА.В.LazarevaA.V.neonatepearl@yandex.ruКатосоваЛ.К.KatosovaL.K.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, МоскваScientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow201116052011103Вопросы современной педиатрии119–123Copyright © Симонова О., Чистякова В., Лазарева А., Катосова Л., 20112011Симонова О., Чистякова В., Лазарева А., Катосова Л.Simonova O., Chistyakova V., Lazareva A., Katosova L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/624ReferencesDemko C.A., Byard P.J., Davis P.B. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 1995; 48 (8): 1041–1049.Demko C.A., Byard P.J., Davis P.B. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 1995; 48 (8): 1041–1049.Döring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cystic. Fibrosis. 2004; 3 (2): 67–69.Döring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cystic. Fibrosis. 2004; 3 (2): 67–69.Canton R., Cobos N., de Gracia J. et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin. Microbiol. Infect. 2005; 11 (9): 690–703.Canton R., Cobos N., de Gracia J. et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin. Microbiol. Infect. 2005; 11 (9): 690–703.Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010; 65 (4): 286–291.Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010; 65 (4): 286–291.Mendelman P.M., Smith A.L., Levy J. et al. Aminogycoside penetration, inactivation and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 1985; 132 (4): 761–765.Mendelman P.M., Smith A.L., Levy J. et al. Aminogycoside penetration, inactivation and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 1985; 132 (4): 761–765.Geller D., Pitlick W.H., Nardella P.A. et аl. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002; 122 (1): 219–226.Geller D., Pitlick W.H., Nardella P.A. et аl. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002; 122 (1): 219–226.Knowels M., Robinson J.M., Wood R.E. et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J. Clin. Invest. 1997; 100 (10): 2588–2595.Knowels M., Robinson J.M., Wood R.E. et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J. Clin. Invest. 1997; 100 (10): 2588–2595.Bush A. et al. Cystic fibrosis in the 21st Century. 2006. Р. 117.Bush A. et al. Cystic fibrosis in the 21st Century. 2006. Р. 117.Eschenbacher W., Boushey H.A., Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. 1984; 129 (2): 211–215.Eschenbacher W., Boushey H.A., Sheppard D. Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am. Rev. Respir. Dis. 1984; 129 (2): 211–215.Chua H.L., Collis G.G., Le Souef P.N. Bronchial response to nebulized antibiotics in children with CF. Eur. Respir. J. 1990; 3: 1114–1116.Chua H.L., Collis G.G., Le Souef P.N. Bronchial response to nebulized antibiotics in children with CF. Eur. Respir. J. 1990; 3: 1114–1116.Dodd M., Abbott J., Maddison J. et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997; 52 (7): 656–658.Dodd M., Abbott J., Maddison J. et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997; 52 (7): 656–658.Moss R. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002; 121 (1): 55–63.Moss R. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002; 121 (1): 55–63.Hodson M., Gallagher C.G., Govan J.R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20 (3): 658–664.Hodson M., Gallagher C.G., Govan J.R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20 (3): 658–664.Grotta M., Etchebere E.C., Ribeiro A.F. et al. Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. J. Bras. Pneumol. 2009; 35 (1): 35–43.Grotta M., Etchebere E.C., Ribeiro A.F. et al. Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa. J. Bras. Pneumol. 2009; 35 (1): 35–43.Семыкин С.Ю., Постников С.С., Поликарпова С.В. и др. Проблемы и перспективы антибактериальной терапии хронической синегнойной инфекции у пациентов с муковисцидозом. Вопросы современной педиатрии. 2010; 2: 94–98.Семыкин С.Ю., Постников С.С., Поликарпова С.В. и др. Проблемы и перспективы антибактериальной терапии хронической синегнойной инфекции у пациентов с муковисцидозом. Вопросы современной педиатрии. 2010; 2: 94–98.Капранов Н.И., Каширская Н.Ю., Никонова В.С. Опыт амбулаторного применения ингаляционных антибиотиков у пациентов с муковисцидозом и синегнойной инфекцией. Лечебное дело. 2010; 3: 64–68.Капранов Н.И., Каширская Н.Ю., Никонова В.С. Опыт амбулаторного применения ингаляционных антибиотиков у пациентов с муковисцидозом и синегнойной инфекцией. Лечебное дело. 2010; 3: 64–68.Симонова О.И. Ингаляционная терапия: от чего зависит ее эффективность? Вопросы современной педиатрии. 2008; 7 (4): 1–5.Симонова О.И. Ингаляционная терапия: от чего зависит ее эффективность? Вопросы современной педиатрии. 2008; 7 (4): 1–5.Симонова О.И., Горинова Ю.В., Лазарева А.В. Первичный высев Pseudomonas aeruginosa при муковисцидозе- не приговор для больного. Российский педиатрический журнал. 2009; 4: 60–63.Симонова О.И., Горинова Ю.В., Лазарева А.В. Первичный высев Pseudomonas aeruginosa при муковисцидозе- не приговор для больного. Российский педиатрический журнал. 2009; 4: 60–63.Mazurek H. et al., Head–to–head comparison of two inhaled tobramycin solutions in cystic fibrosys (CF) patients with chronic Pseudomonas aeruginosa (Pa) infection. J. Cystic. Fibr. 2011; 29 (Abstract №110).Mazurek H. et al., Head–to–head comparison of two inhaled tobramycin solutions in cystic fibrosys (CF) patients with chronic Pseudomonas aeruginosa (Pa) infection. J. Cystic. Fibr. 2011; 29 (Abstract №110).
The authors declare that there are no conflicts of interest present.